These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 21944383)

  • 21. Failure of erythropoietin to render jeopardized ischemic myocardium amenable to incremental salvage by early reperfusion.
    French CJ; Zaman AK; Sobel BE
    Coron Artery Dis; 2009 Jun; 20(4):295-9. PubMed ID: 19440068
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Postinfarct active cardiac-targeted delivery of erythropoietin by liposomes with sialyl Lewis X repairs infarcted myocardium in rabbits.
    Yamada Y; Kobayashi H; Iwasa M; Sumi S; Ushikoshi H; Aoyama T; Nishigaki K; Takemura G; Fujiwara T; Fujiwara H; Kiso M; Minatoguchi S
    Am J Physiol Heart Circ Physiol; 2013 Apr; 304(8):H1124-33. PubMed ID: 23417861
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of erythropoietin on angiogenesis after myocardial infarction in porcine.
    Kawachi K; Iso Y; Sato T; Wakabayashi K; Kobayashi Y; Takeyama Y; Suzuki H
    Heart Vessels; 2012 Jan; 27(1):79-88. PubMed ID: 22038108
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intravenous infusion of mesenchymal stem cells enhances regional perfusion and improves ventricular function in a porcine model of myocardial infarction.
    Halkos ME; Zhao ZQ; Kerendi F; Wang NP; Jiang R; Schmarkey LS; Martin BJ; Quyyumi AA; Few WL; Kin H; Guyton RA; Vinten-Johansen J
    Basic Res Cardiol; 2008 Nov; 103(6):525-36. PubMed ID: 18704259
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Positive effect of darbepoetin on peri-infarction remodeling in a porcine model of myocardial ischemia-reperfusion.
    Toma C; Letts DP; Tanabe M; Gorcsan J; Counihan PJ
    J Mol Cell Cardiol; 2007 Aug; 43(2):130-6. PubMed ID: 17597149
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Complementary therapeutic effects of dual delivery of insulin-like growth factor-1 and vascular endothelial growth factor by gelatin microspheres in experimental heart failure.
    Cittadini A; Monti MG; Petrillo V; Esposito G; Imparato G; Luciani A; Urciuolo F; Bobbio E; Natale CF; Saccà L; Netti PA
    Eur J Heart Fail; 2011 Dec; 13(12):1264-74. PubMed ID: 22045926
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prolonged therapy with erythropoietin is safe and prevents deterioration of left ventricular systolic function in a porcine model of myocardial infarction.
    Angeli FS; Amabile N; Burjonroppa S; Shapiro M; Bartlett L; Zhang Y; Virmani R; Chatterjee K; Boyle A; Grossman W; Yeghiazarians Y
    J Card Fail; 2010 Jul; 16(7):579-89. PubMed ID: 20610234
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term effects of growth hormone on infarct size and left ventricular function in sheep with coronary artery occlusion.
    Olea FD; De Lorenzi A; Cortés C; Cabeza Meckert P; Cendoya O; Barra JG; Bercovich A; González E; Laguens R; Crottogini A
    J Cardiovasc Pharmacol; 2010 Mar; 55(3):255-61. PubMed ID: 20051878
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Erythropoietin improves cardiac function through endothelial progenitor cell and vascular endothelial growth factor mediated neovascularization.
    Westenbrink BD; Lipsic E; van der Meer P; van der Harst P; Oeseburg H; Du Marchie Sarvaas GJ; Koster J; Voors AA; van Veldhuisen DJ; van Gilst WH; Schoemaker RG
    Eur Heart J; 2007 Aug; 28(16):2018-27. PubMed ID: 17576662
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Post-infarct treatment with an erythropoietin-gelatin hydrogel drug delivery system for cardiac repair.
    Kobayashi H; Minatoguchi S; Yasuda S; Bao N; Kawamura I; Iwasa M; Yamaki T; Sumi S; Misao Y; Ushikoshi H; Nishigaki K; Takemura G; Fujiwara T; Tabata Y; Fujiwara H
    Cardiovasc Res; 2008 Sep; 79(4):611-20. PubMed ID: 18541523
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Beneficial effects of diltiazem during myocardial reperfusion: a randomized trial in acute myocardial infarction.
    Pizzetti G; Mailhac A; Li Volsi L; Di Marco F; Lu C; Margonato A; Chierchia SL
    Ital Heart J; 2001 Oct; 2(10):757-65. PubMed ID: 11721720
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Erythropoietin treatment in patients with acute myocardial infarction: a meta-analysis of randomized controlled trials.
    Gao D; Ning N; Niu X; Dang Y; Dong X; Wei J; Zhu C
    Am Heart J; 2012 Nov; 164(5):715-727.e1. PubMed ID: 23137502
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chronic erythropoietin treatment decreases post-infarct myocardial damage in rats without venous thrombogenic effect.
    Prunier F; Pottier P; Clairand R; Mercier A; Hajjar RJ; Planchon B; Furber A
    Cardiology; 2009; 112(2):129-34. PubMed ID: 18596374
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of system delay on infarct size, myocardial salvage index, and left ventricular function in patients with ST-segment elevation myocardial infarction.
    Lønborg J; Schoos MM; Kelbæk H; Holmvang L; Steinmetz J; Vejlstrup N; Jørgensen E; Helqvist S; Saunamäki K; Bøtker HE; Kim WY; Terkelsen CJ; Clemmensen P; Engstrøm T
    Am Heart J; 2012 Oct; 164(4):538-46. PubMed ID: 23067912
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Constitutively overexpressed erythropoietin reduces infarct size in a mouse model of permanent coronary artery ligation.
    Camici GG; Stallmach T; Hermann M; Hassink R; Doevendans P; Grenacher B; Hirschy A; Vogel J; Lüscher TF; Ruschitzka F; Gassmann M
    Methods Enzymol; 2007; 435():147-55. PubMed ID: 17998053
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A single-center prospective randomized controlled trial evaluating the safety and efficacy of IntraCoronary Erythropoietin delivery BEfore Reperfusion: gauging infarct size in patients with acute ST-segment elevation myocardial infarction. Study design and rationale of the 'ICEBERG Trial'.
    Suh JW; Yoon YE; Oh IY; Yoon CH; Cho YS; Youn TJ; Chae IH; Choi DJ
    Contemp Clin Trials; 2013 May; 35(1):145-50. PubMed ID: 23506972
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cardiac endothelin release and infarct size, myocardial blood flow, and ventricular function in canine infarction and reperfusion.
    Kelly RF; Hursey TL; Schaer GL; Piotrowski MJ; Dee SV; Parrillo JE; Hollenberg SM
    J Investig Med; 1996 Dec; 44(9):575-82. PubMed ID: 9035612
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combining erythropoietin infusion with intramyocardial delivery of bone marrow cells is more effective for cardiac repair.
    Zhang D; Zhang F; Zhang Y; Gao X; Li C; Yang N; Cao K
    Transpl Int; 2007 Feb; 20(2):174-83. PubMed ID: 17239026
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mesenchymal stem cells are superior to angiogenic growth factor genes for improving myocardial performance in the mouse model of acute myocardial infarction.
    Shyu KG; Wang BW; Hung HF; Chang CC; Shih DT
    J Biomed Sci; 2006 Jan; 13(1):47-58. PubMed ID: 16283432
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characterization of microvascular dysfunction after acute myocardial infarction by cardiovascular magnetic resonance first-pass perfusion and late gadolinium enhancement imaging.
    Yan AT; Gibson CM; Larose E; Anavekar NS; Tsang S; Solomon SD; Reynolds G; Kwong RY
    J Cardiovasc Magn Reson; 2006; 8(6):831-7. PubMed ID: 17060106
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.